Soguimap Sarl Pharmaceutical Import Profile — Guinea (DGFT 2022–2026)

Name: Soguimap Sarl Pharmaceutical Import Records from India — 3 Products, $446.3K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Soguimap Sarl — Pharmaceutical Importer Profile (2026) | 3 Products, $446.3K Trade | TransData Nexus

Soguimap Sarl

Pharmaceutical Importer · Guinea · Antifungals Focus · $446.3K Total Trade · DGFT Verified

Soguimap Sarl is a pharmaceutical importer based in Guinea with a total trade value of $446.3K across 3 products in 3 therapeutic categories. Based on 10 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Soguimap Sarl sources from 2 verified Indian suppliers, with Unilink Pharma Private Limited accounting for 95.0% of imports.

Soguimap Sarl — Import Portfolio & Supplier Network

Soguimap Sarl import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Soguimap Sarl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Unilink Pharma Private Limited	$2.1M	189	95.0%
Aura Inc	$111.9K	28	5.0%

Soguimap Sarl sources from 2 verified Indian suppliers across 145 distinct formulations. The sourcing is highly concentrated — Unilink Pharma Private Limited accounts for 95.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Soguimap Sarl Import?

Formulation	Value	Ships
Unimoxi capsules(amoxicillin	$251.3K	6
Benzoic acid and salicylic acid	$106.0K	3
Miconazole nitrate cream 30g -19910	$105.0K	3
Primaderm cream - 9390	$103.8K	3
Artesunate injection 60MG 7500 aihi	$102.5K	3
Silden -50 sildenafil citiate BP eq to	$102.5K	3
Multivitamin syrup -4895	$102.4K	3
Sulfadoxine & pyrimethamine tablets	$100.9K	4
Ferrous sulfate 200MG + folic acid	$50.0K	1
Unimoxi(amoxicillin capsules BP 500 MG)-1504000	$50.0K	1
Ceftriaxone injection USP 1g -162400	$40.6K	1
Ceftriaxone injection USP 1g 79990	$40.0K	2
Hyoscine butylbromide injection BP	$36.4K	1
Water for injection BP 5ML -1302400	$32.6K	1
Cloxacillin sodium capsules USP 500 MG -301500	$31.2K	2

Soguimap Sarl imports 145 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Miconazole	Antifungals	$150.0K	3	0.8%	2
2	Salicylic	Combination Drugs	$150.0K	3	0.9%	4
3	Sulfadoxine	Antimalarial & Antiparasitic	$146.3K	4	0.3%	14

Soguimap Sarl imports 3 pharmaceutical products across 3 categories into Guinea totaling $446.3K.

Soguimap Sarl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Soguimap Sarl is a prominent pharmaceutical wholesaler and distributor based in Conakry, Guinea. With over 20 years of experience, the company has been dedicated to supplying the Guinean population with quality medications at affordable prices. Their mission centers on enhancing public health by providing certified medicines through a reliable and efficient distribution network.

The company operates as a grossiste répartiteur en pharmacie, which translates to a pharmaceutical wholesaler-distributor. This role involves sourcing, storing, and distributing pharmaceutical products to various healthcare providers across Guinea. Soguimap Sarl emphasizes quality, reliability, integrity, innovation, and social responsibility in its operations, aiming to improve accessibility to healthcare products nationwide.

2Distribution Network

Soguimap Sarl's distribution network is strategically located in Conakry, the capital city of Guinea, facilitating efficient access to the country's primary urban centers. The company's facilities are equipped with modern and secure storage infrastructures, ensuring optimal preservation of pharmaceutical products. Their logistics system is designed for rapid and precise delivery, adhering to health standards and maintaining product integrity throughout the distribution process.

3Industry Role

In Guinea's pharmaceutical supply chain, Soguimap Sarl functions as a primary wholesaler and distributor. By sourcing medications from international suppliers, particularly from India, and distributing them to local pharmacies, hospitals, and clinics, the company plays a crucial role in ensuring the availability of essential medicines across the nation. Their operations are integral to the healthcare sector, bridging the gap between global pharmaceutical manufacturers and the Guinean market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Soguimap Sarl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Soguimap Sarl's sourcing strategy exhibits a high degree of concentration, primarily importing finished pharmaceutical formulations from two Indian suppliers: Unilink Pharma Private Limited and Aura Inc. Unilink Pharma Private Limited accounts for 95% of the shipments, while Aura Inc. contributes 5%. This concentration suggests a strategic choice to maintain strong, reliable partnerships with established suppliers, ensuring consistent product quality and supply. However, such dependency also poses risks; any disruption with these suppliers could significantly impact Soguimap Sarl's ability to meet domestic demand. The stability of these relationships is crucial for the company's operational continuity.

2Supply Chain Resilience

Soguimap Sarl's supply chain resilience is closely tied to its reliance on two primary Indian suppliers. The company's import data indicates a focus on a limited range of pharmaceutical formulations, which may limit its ability to diversify sourcing in response to supply chain disruptions. Additionally, the concentration of shipments from a single supplier could expose the company to risks associated with geopolitical issues, regulatory changes, or logistical challenges in the supplier's country. Ensuring compliance with international quality standards, such as WHO GMP, is essential for maintaining product integrity and meeting regulatory requirements in Guinea.

Importing Pharmaceuticals into Guinea — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Guinea

1Regulatory Authority & Framework

In Guinea, the National Directorate of Medicines and Pharmacies (Direction Nationale du Médicament et des Pharmacies, DNMP) is the primary regulatory authority overseeing pharmaceutical imports, marketing authorizations, and the enforcement of health regulations. The DNMP is responsible for ensuring that imported pharmaceutical products meet the country's health and safety standards. Additionally, the National Ethics Committee for Health Research (Comité National d'Éthique pour la Recherche en Santé, CNERS) plays a role in reviewing health research protocols, which may intersect with pharmaceutical importation processes.

2Import Licensing & GMP

Importers in Guinea are required to obtain formal import authorization, known as Demande Déscriptive d’Importation (DDI), from the Ministry of Commerce for quantities exceeding 12 million GNF (approximately USD 1,250). This process involves submitting a descriptive import application prior to the opening of a virtual transactions folder. Regarding Good Manufacturing Practice (GMP) certifications, Guinea recognizes international standards such as WHO GMP, EU GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certificates to comply with regulatory requirements.

Quality & Labeling

Soguimap Sarl — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Soguimap Sarl's focus on importing antifungal, combination drugs, and antimalarial & antiparasitic medications aligns with the prevalent health challenges in Guinea. The high import values of miconazole, salicylic acid, and sulfadoxine suggest a strategic emphasis on addressing common conditions such as fungal infections, skin disorders, and malaria. This product strategy is driven by the significant demand for these treatments within the Guinean population, aiming to improve public health outcomes by providing accessible and effective pharmaceutical solutions.

2Sourcing Profile

Soguimap Sarl's sourcing strategy is centered on importing generic drug formulations, primarily from India, which offers a diverse range of cost-effective pharmaceutical products. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a focus on ready-to-use products that meet the immediate needs of the Guinean market. India's established pharmaceutical industry, known for its adherence to international quality standards, aligns with Soguimap Sarl's commitment to providing reliable and safe medications to its customers.

3Market Positioning

Seller's Guide — How to Become a Supplier to Soguimap Sarl

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Guinean market by partnering with Soguimap Sarl. The company's established distribution network and focus on high-demand therapeutic areas present avenues for expanding product offerings. Potential gaps in Soguimap Sarl's current sourcing include the need for additional suppliers to mitigate risks associated with over-reliance on a limited number of sources. Indian exporters can explore these opportunities by ensuring compliance with Guinea's regulatory requirements and aligning their product portfolios with the therapeutic needs of the Guinean population.

2Requirements & Qualifications

Indian exporters aiming to supply Soguimap Sarl and the Guinean market must ensure that their products comply with international quality standards, such as WHO GMP, EU GMP, or PIC/S certifications. Importers are required to obtain formal import authorization from the Ministry of Commerce for quantities exceeding 12 million GNF. Additionally, products must meet Guinea's labeling requirements, including French language labeling and adherence to batch testing and stability standards. Ensuring these qualifications will facilitate smoother market entry and regulatory compliance.

How to Approach

Frequently Asked Questions — Soguimap Sarl

What products does Soguimap Sarl import from India?

Soguimap Sarl imports 3 pharmaceutical products across 3 categories. Top imports: Miconazole ($150.0K), Salicylic ($150.0K), Sulfadoxine ($146.3K).

Who supplies pharmaceuticals to Soguimap Sarl from India?

Soguimap Sarl sources from 2 verified Indian suppliers. The primary supplier is Unilink Pharma Private Limited (95.0% of imports, $2.1M).

What is Soguimap Sarl's total pharmaceutical import value?

Soguimap Sarl's total pharmaceutical import value from India is $446.3K, based on 10 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Soguimap Sarl focus on?

Soguimap Sarl imports across 3 categories. The largest: Antifungals (33.6%), Combination Drugs (33.6%), Antimalarial & Antiparasitic (32.8%).

Get Full Soguimap Sarl Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.